Purpose: This review aims to introduce the previous autologous invariant natural killer T (iNKT) cell-targeted cancer immunotherapy and an ongoing clinical trial using allogeneic induced pluripotent stem cell-derived NKT cells (iPS-NKT cells) for head and neck cancer (HNC).
No takes yet. Share an insight, caveat, or question.
Shinichiro Motohashi (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: